Is ‘Maintenance Therapy’ in Metastatic Breast Cancer a Misnomer?

Podcast

Ron Piana, Executive Editor for Special Projects with the journal ONCOLOGY, spoke with nationally regarded breast cancer specialist, Dr. Debu Tripathy, co-course director for the 27th Annual Miami Breast Cancer Conference.

Debu Tripathy, MD

Debu Tripathy, MD

Dr. Debu Tripathy, co-course director for the 27th Annual Miami Breast Cancer Conference sheds light on his presentation, The Role of Maintenance Therapy for Metastatic Breast Cancer, truly a complicated and controversial topic.

-Interviewed by Ron Piana

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
Breast oncologist Jade E. Jones, MD, says she tries to send patients with BRCA-mutant HR-positive TNBC to clinical trials that use PARP inhibitors.
Following progression on a CDK4/6 inhibitor, ascertaining the endocrine sensitivity of HR-positive/HER2-negative disease may inform sequential treatment.
T-DXd improved progression-free survival over standard chemotherapy among patients with HR-positive/triple-negative breast cancer in DESTINY-Breast04.
The use of chemotherapy trended towards improved recurrence-free intervals in older patients with high-risk tumors as determined via the MammaPrint assay.
Use of a pharmacist-directed resource appears to improve provider confidence and adverse effect monitoring for patients undergoing infusion therapy.
Reshma L. Mahtani, DO, describes how updates from the DESTINY-Breast09, ASCENT-04, and VERITAC-2 trials may shift practices in the breast cancer field.
Related Content
4 Evaluating AI-Driven Responses in Breast Reconstruction: A Comparative Study of Response Formats

4 Evaluating AI-Driven Responses in Breast Reconstruction: A Comparative Study of Response Formats

Tarbia Hamid;Laura Manfroi;Hiral Thakkar;Samir Mitri
July 14th 2025
Article
Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.

Eliminating Racial Disparities in Guideline-Concordant Breast Cancer Care

Oluwadamilola “Lola” Fayanju, MD, MA, MPHS, FACS
April 21st 2025
Podcast

Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.

6 Peer Support Programming Among Women At-Risk for Surviving Breast Cancer: Facilitators and Barriers to Community-Based Patient Navigation and the Role of Quality of Life

6 Peer Support Programming Among Women At-Risk for Surviving Breast Cancer: Facilitators and Barriers to Community-Based Patient Navigation and the Role of Quality of Life

Muriel Statman;Marcelo Sleiman Jr;Duye Liu;Anthony Zisa;Adina Fleischmann;Kenneth Tercyak
July 12th 2025
Article
Paolo Tarantino, MD, and Matteo Lambertini, MD, PhD discuss findings related to CDK4/6 inhibitors and antibody drug conjugates presented at SABCS 2024.

SABCS 2024 Data Show ‘Great Steps Forward’ in Breast Cancer Care

Paolo Tarantino, MD;Matteo Lambertini, MD
January 13th 2025
Podcast

Paolo Tarantino, MD, and Matteo Lambertini, MD, PhD discuss findings related to CDK4/6 inhibitors and antibody drug conjugates presented at SABCS 2024.

7 Metaplastic Breast Cancer: A Retrospective Chart Review of Clinical Features

7 Metaplastic Breast Cancer: A Retrospective Chart Review of Clinical Features

Nidhi Navaratna;Mariam Aoun;Nitya Batra;Mohammad Muhsin Chisti, MD
July 11th 2025
Article

8 A Case Series Exploring Characteristics and Outcomes of Metachronous Primary Breast and Lung Cancer in a Diverse Cohort

8 A Case Series Exploring Characteristics and Outcomes of Metachronous Primary Breast and Lung Cancer in a Diverse Cohort

Keerthana Sureshkumar;Richa Dawar
July 10th 2025
Article